Table 1.
Baseline Characteristics of Patients Randomized to MTX + Etanercept, Triple Therapy, or MTX Monotherapy
| MTX + ETA N=155 | Triple Therapy N=78 | MTX Monotherapy N=226 | |
|---|---|---|---|
| Demographics and RA related variables | |||
| Age (years) | 50.8 ± 13.2 | 47.6 ± 12.4 | 49.0 ± 12.2 |
| BMI | 29.0 ± 6.9 | 29.6 ± 8.6 | 30.2 ± 7.0 |
| Female | 73.6% | 76.9% | 70.8% |
| RF+ | 88.4% | 92.3% | 87.6% |
| Smoking (current) | 34.8% | 30.8% | 33.6% |
| Disease Duration (months) | 3.5 ± 6.6 | 5.1 ± 8.5 | 3.6 ± 6.3 |
| DAS28(ESR) | 5.7 ± 1.1 | 5.8 ± 1.1 | 5.8 ± 1.1 |
| CRP (mg/dL) | 1.6 ± 2.7 | 1.5 ± 2.4 | 1.6 ± 2.0 |
| Race | |||
| African American | 10.3% | 7.7% | 10.2% |
| Caucasian | 80.0% | 76.9% | 82.7% |
| Other | 9.7% | 15.4% | 7.1% |
| Medications | |||
| Any oral glucocorticoid use | 43.9% | 47.4% | 42.0% |
| Statins | 15.5% | 10.3% | 11.5% |
| Comorbidities | |||
| Diabetes | 79.4% | 87.2% | 81.4% |
| Cardiovascular disease* | 29.7% | 24.4% | 27.4% |
| Respiratory disease** | 23.2% | 16.7% | 16.4% |
| Lipid levels at baseline | |||
| Total Cholesterol, mg/dL | 189.3 ± 44.7 | 183.3 ± 44.9 | 189.4 ± 48.2 |
| LDL-C, mg/dL | 107.0 ± 35.1 | 96.1 ± 31.2 | 107.1 ± 38.0 |
| HDL-C, mg/dL | 56.2 ± 14.7 | 57.9 ± 19.8 | 54.4 ± 14.8 |
| Ratio between Total Cholesterol and HDL-C | 3.5 ± 0.9 | 3.3 ± 0.8 | 3.6 ± 0.9 |
Data shown as mean ± SD, or n (%); HDL-C = high density lipoprotein cholesterol; LDL-C = low density lipoprotein cholesterol; CRP = C-reactive protein; DAS28 = disease activi9ty score in 28 joints; ESR = erythrocyte sedimentation rate. MTX = methotrexate; ETA = etanercept.
*
includes history of myocardial infarction, heart failure, unstable angina, angioplasty, stent placement, coronary bypass graft angioplasty and stroke.
**
includes asthma, chronic obstructive pulmonary disease and other chronic pulmonary disorders.